

1 **Characteristics and antiviral treatment eligibility of newly**
2 **diagnosed hepatitis B patients at a teaching hospital in**
3 **Ghana: Implications for prevention and management**

4
5
6 Joseph Daniels^{1,2*}, Yvonne A. Nartey³, Francis Djankpa⁴, Jacques Simpore⁵, Dorcas Obiri-
7 Yeboah²

8
9
10 ¹National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching
11 Hospital, Accra, Ghana

12 ²Department of Microbiology and Immunology, School of Medical Sciences, University of
13 Cape Coast, Cape Coast, Ghana

14 ³Department of Internal Medicine and Therapeutics, School of Medical Sciences, University
15 of Cape Coast, Cape Coast, Ghana

16 ⁴Department of Physiology, School of Medical Sciences, University of Cape Coast, Cape
17 Coast, Ghana

18 ⁵Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso

19

20

21 * Corresponding author

22 Email: j.daniels@kbth.gov.gh (JD)

23

24 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

25 **Abstract**

26 Hepatitis B virus (HBV) infection poses a considerable public health challenge in limited-
27 resource settings especially in the sub-Saharan African region. Even though HBV infection is
28 incurable, timely treatment is effective in preventing disease progression to liver cirrhosis or
29 hepatocellular carcinoma. However, not all infected patients require treatment. The aim of this
30 study was to determine the clinical, immunological, and virological profiles of newly
31 diagnosed adult HBV patients at a tertiary healthcare center in Ghana and to determine the
32 antiviral treatment eligibility rate based on current guidelines of the World Health Organization
33 (WHO). A hospital-based cross-sectional study involving total sampling of 220 treatment naïve
34 HBV surface antigen positive clients was carried out. A structured questionnaire was used to
35 collect data and detailed clinical and laboratory assessment (serological, biochemical and
36 virological) was carried out. Data were entered and analyzed with STATA version 16. The
37 median age at diagnosis was 34 years (IQR 26.0 – 41.5) with a male to female ratio of 1:1.5.
38 A total of 138 participants (62.7%) were diagnosed with HBV infection following voluntary
39 testing. There was a median delay of 8.5 months (IQR 3.0 – 22.5) between initial diagnosis and
40 patients' presentation for medical care. In all, 24 patients (10.9%) had abnormal clinical
41 examination findings, 172 patients (78.2%) had HBV DNA levels \leq 2000 IU/ml while 8 (3.6%)
42 were seropositive for HBeAg. A small proportion of patients had concomitant human
43 immunodeficiency virus (2.7%) and hepatitis C virus (1.4%) infections. Treatment eligibility
44 rate was very low among newly diagnosed HBV infected patients seeking medical care (n=14,
45 6.4%) following the WHO guidelines for treatment eligibility. Thus, increasing screening rate
46 among the general population, early linkage to clinical care of screen positives and vaccination
47 of screen negatives will help reduce HBV related clinical conditions in resource limited
48 countries.

49 **Keywords**

50 HBV DNA, HBV/HCV coinfection, HBV/HIV coinfection, hepatitis B infection

51 hepatitis B, immunological profile, hepatitis B, treatment eligibility

52

53 **Introduction**

54 Estimated global prevalence rates in 2022, based on data from 170 countries suggest that
55 about 257.5 million individuals worldwide have confirmed hepatitis B virus (HBV) infection
56 [1]. About 0.5% of infected people yearly seroconvert spontaneously from being hepatitis B
57 surface antigen (HBsAg) positive to becoming hepatitis B surface antibody (HBsAb) positive
58 [2]. The overall global lifetime risk of HBsAg seropositivity is estimated to be more than 60%
59 [3]. The World Health Organization (WHO) estimates the occurrence of 1.5 million new
60 infections around the globe every year. HBV infects the liver and is known to be a major global
61 cause of both acute and chronic hepatic diseases [4]. HBV infection is also reported to be the
62 cause for about 50 - 80% of all diagnosed cases of hepatocellular carcinomas (HCC) globally
63 [5]. Additionally, it is estimated to cause between 500,000 and 1.2 million deaths worldwide
64 annually through chronic hepatitis, and associated complications such as liver cirrhosis and
65 HCC [6].

66 HBV infection poses a considerable public health challenge in the developing world
67 especially African countries [7]. In Africa unlike other regions of the world, HCC and liver
68 cirrhosis develop at an earlier age among patients with HBV infection, and are generally
69 associated with poorer prognosis [8]. The highest prevalence of HBsAg seropositivity is found
70 in the WHO Western Pacific Region and Africa with 116 million and 81 million people
71 respectively reported to be chronically infected [4]. In Ghana, there is high (>8%) prevalence
72 of hepatitis B infection per the WHO classification [9]. Different experts have reported national

73 prevalence rates of 8.48% [10], 10-15% [11] as well as 12.92% [2]. However, a recent meta-
74 analysis of 21 studies conducted in Ghana between 2015 and 2019 reported hepatitis B
75 infection rates of 8.36% and 14.3% among adults and adolescents respectively [12]. HBV
76 infection requires great attention in Ghana due to its significant public health importance.
77 HBsAg detection remains the primary tool for the screening of individuals for HBV in sub-
78 Saharan Africa [13]. A positive test for HBsAg for more than 6 months coupled with
79 seropositivity for hepatitis B core immunoglobulin G (HBcAb – IgG) imply disease chronicity
80 with increased risk of developing cirrhosis, hepatic decompensation and HCC [14].

81 Not all patients who test positive for HBsAg require treatment. Patients' eligibility for
82 the commencement of antiviral therapy is dependent on key factors such as age, HBV viral
83 load, serum Alanine Transaminase (ALT) levels, Aspartate to Platelet Ratio Index (APRI),
84 clinical evidence of liver cirrhosis, hepatitis B envelope antigen (HBeAg) status, concomitant
85 hepatitis C virus (HCV) or human immunodeficiency virus (HIV) coinfection and pregnancy
86 status among females [15, 16]. It is important to accurately classify patients based on these
87 parameters, since this directly influences clinical decisions regarding antiviral therapy. These
88 parameters are also important in identifying patients at risk of progression to liver cirrhosis or
89 cancer, and as such determine which individuals require immediate initiation of antiviral
90 therapy.

91 With the high endemicity of chronic HBV (CHB) infection in Ghana, it is important to
92 determine the proportion of HBV patients who require treatment. It is equally important to
93 identify those who present for the first time with complications such as cirrhosis, hepatic
94 decompensation and HCC, since this highlights missed opportunities for the care and
95 management of persons living with HBV. The aim of this study was to determine the clinical,
96 immunological, and virological profiles of newly diagnosed adult HBV infected patients at a

97 tertiary healthcare facility in Ghana and to determine the antiviral treatment eligibility rate
98 based on WHO guidelines.
99

100 **Methods**

101 **Study design and setting**

102 This was a hospital-based cross-sectional study. Participants were recruited into the
103 study from the viral hepatitis/ sexually transmitted infections (STIs) clinic at the Cape Coast
104 Teaching Hospital (CCTH) which is situated at the northern part of the Cape Coast metropolis
105 in the Central Region of Ghana. CCTH is a 400-bed capacity hospital that serves as the tertiary
106 care referral center for both private and public healthcare institutions in the central and western
107 region of Ghana. The clinic started operating in 2009 and had registered about 3000 clients
108 with HBV infection by 2021. CCTH provides comprehensive HBV care and runs a specialist-
109 led gastrointestinal (GI) and hepatology clinic that manages patients with diseases of the GI
110 and hepatobiliary tracts including those with complications related to viral hepatitis such as
111 liver cirrhosis and hepatocellular carcinoma.

112 **Study Participants**

113 Participants were recruited over a cumulative period of 11 months from December 10,
114 2019 to June 09, 2020 and November 03, 2020 to February 09, 2021 due to interruptions to the
115 operations of the clinic caused by the COVID-19 pandemic. Samples were collected at the
116 clinic once a week. There was total population sampling of all newly diagnosed clients with
117 HBV infection who were seeking clinical care at CCTH during the sampling period. Patients
118 included in this study were treatment naïve adult clients who were 18 years or older, with a
119 positive HBsAg test who provided written informed consent. All patients with known
120 HBV/HIV coinfection who were already on highly active antiretroviral therapy (HAART) were

121 excluded from the study as well as individuals on antiviral therapy for other conditions if their
122 medications were known to be simultaneously active against HBV infection. All patients who
123 had been previously treated for HBV infection were also excluded from the study.

124 **Study size**

125 All clients attending the clinic who met the inclusion criteria (n=231 over the recruitment
126 period) were offered the opportunity to be part of the study. However, 11 (4.8%) eligible clients
127 declined to provide informed consent to participate in the study for personal reasons. In all,
128 220 patients were recruited into the study.

129 **Ethical considerations**

130 The study was approved by the institutional review board of CCTH (Reference number:
131 CCTHERC/EC/2019/084). All patients' information including laboratory test results were kept
132 private and confidential. The data of the participants were anonymized prior to analysis.
133 Throughout this study, there was strict adherence to the prescribed standards of acceptable
134 scientific and ethical behavior. All relevant COVID-19 protocols were observed during
135 interactions with patients and data collection. All the study participants provided written
136 informed consent prior to their recruitment into the study.

137 **Data sources**

138 Data regarding socio-demographic characteristics, past medical and family history as
139 well as other relevant factors linked to HBV infection were collected through a structured
140 questionnaire which comprised 32 closed-ended questions. Relevant data were also abstracted
141 from patients' hospital records with their consent. The questionnaire was pretested in a similar
142 out-patient setting to determine its validity and reliability to ascertain its appropriateness for
143 this study. Twenty-two (22) clients were selected for pretesting, representing 10% of the actual
144 sample size. Tau-equivalent reliability, also known as Cronbach's Alpha (α) was computed to

145 determine the reliability coefficient. The Alpha value obtained was 0.72 (number of items =
146 32), therefore this research instrument was deemed reliable and acceptable for collecting useful
147 data for the study.

148 **Laboratory Procedures / Analysis**

149 Single-use commercially available First Response® HBsAg rapid test kits (Premier
150 Medical Corporation Private Limited, India) were used to qualitatively detect HBsAg in
151 the plasma specimen of patients [17]. Using the COBAS® AmpliPrep / COBAS® TaqMan®
152 HBV Test, version 2.0 (Roche, Switzerland) (CAP-CTM) and in accordance with the
153 manufacturer's instructions, the HBV viral load was measured from 400µl of patients' blood
154 [18]. The Biopanda HBV Combo Rapid Test (RAPG-HBV-001) (Biopanda, United Kingdom)
155 was utilized to qualitatively detect HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in patients'
156 blood samples. The ChemWell® 2910 Automated EIA and Chemistry Analyzer (Awareness
157 Technologies, USA) was used to measure serum electrolytes, blood urea nitrogen (BUN) and
158 liver enzymes including aspartate and alanine transaminases, strictly following the
159 manufacturer's protocol. Complete blood counts (CBCs) were determined using the
160 Mindray BC-2800 Auto Hematology Analyzer (China) [19]. All the patients were also tested
161 for HIV infection using the First Response® HIV 1-2.O test (Premier Medical Corporation
162 Private Limited, India), OraQuick® HIV test (OraSure Technologies, USA) and SD
163 Bioline™ HIV-1/2 antibody test kits (Abbott, USA) based on the guidelines for HIV screening
164 and diagnosis among adults, pregnant women and adolescents in healthcare settings [20].
165 Single use commercially available HCV rapid test kits (Advanced Diagnostic Kit for
166 immunoglobulin to HCV, China) were used to qualitatively detect the presence of anti-HCV
167 immunoglobulins in patients' samples with sensitivity of 99.0% and specificity of 99.8% [21].
168 APRI calculation was based on hematological and biochemical tests conducted on patients'
169 samples. APRI was computed with the formula $(AST/40/ \text{platelet count } (10^9/L) \times 100)$ [22].

170 **Statistical analysis**

171 Data were anonymized, coded, statistically cleaned, and analyzed using STATA
172 statistical software package version 16 for Microsoft windows (Stata Corp). A combination of
173 descriptive and inferential statistics was performed. Socio-demographic and other
174 characteristics of participants were presented as frequencies with percentages. Histogram and
175 Shapiro-Wilk's test were used to assess normality of the data. Means and standard deviations
176 were used for normally distributed data while median and interquartile range were used for
177 skewed data. For this study, $p \leq 0.05$ was considered statistically significant at a 95%
178 confidence interval.

179

180 **Results**

181 **Socio-demographic and behavioral characteristics**

182 In total, 220 individuals with confirmed hepatitis B viral infection participated in this
183 study. A total of 131 (59.6%) of the participants were female whereas 109 (40.4%) were male.
184 There were more females than males in all age categories (Fig 1).

185

186 **Fig 1. Percentage distribution of patients by age and gender.**

187

188 The median age was 34 years (IQR 26.0 – 41.5). One hundred and eight (49.0%) were
189 single whilst the remaining (n=112, 51.0%) were either married, divorced, or widowed.
190 Majority (n=143, 65.0%) were sexually active. The median interval between initial diagnosis
191 and presentation at the clinic was 8.5 months (IQR 3.0 – 22.5), with about a third of the patients
192 (61.8%) attending their first visit to the clinic more than a year after initial diagnosis (Table 1).

193

194

195

196

197 **Table 1. Socio-demographic and behavioral characteristics (n=220).**

Variables	Categories	Number (n)/ Median	Percentage (%)/ IQR
Age (years)	Median	34	26.0 – 41.5
	≤ 30	83	37.7
	31 – 50	110	50.0
	> 50	27	12.3
Marital status	Single	108	49.0
	Married	100	45.5
	Divorced/ Widowed	12	5.5
Sexual activity	Active	143	65.0
	Inactive	77	35.0
Pregnancy status of females (n = 131)	Pregnant	9	6.9
	Not-pregnant	122	93.1
Time since initial diagnosis (years)	Median	8.5	3.0 – 22.5
	≤ 1	136	61.8
	1 – 5	65	29.6
	> 5	19	8.6
History of alcohol intake	Yes	30	13.6
	No	190	86.4

Variables	Categories	Number (n)/ Median	Percentage (%)/ IQR
Smoking habit	Smokers	6	2.7
	Non-smokers	214	97.3

198 IQR: interquartile range

199 Most of the participants (n = 138, 62.7%) were initially diagnosed with HBV infection
200 due to voluntary testing whereas 19 females (8.6%) were diagnosed as part of routine ANC
201 screening. A few (n = 8, 3.6%) were diagnosed through screening after the diagnosis of close
202 associates (sexual partners & family members) whereas the remainder (n=55, 25.0%) were
203 diagnosed after testing pursuant to the recommendation of a health-worker (Fig 2).

204

205 **Fig 2. Circumstances leading to initial diagnosis among study participants (n = 220).**

206 ANC: antenatal care.

207

208 Approximately 60.9% did not know the HBsAg status of their immediate family
209 members whereas 20.5% had a positive family history of HBV infection. In all, 15 (6.8%) had
210 parents with HBV infection as illustrated in Fig 3.

211

212 **Fig 3. Distribution of HBV seropositive family members and sexual partners of the**
213 **study participants.**

214

215 In all, 24 patients (10.9%) had abnormal clinical examination findings. There were 12
216 patients (5.5%) who had icterus (jaundice), whereas 3 (1.4%) had hepatomegaly as illustrated

217 in Fig 4 which shows the distribution of clinical examination findings among patients. Two
218 patients (0.9%) each had abdominal distension and other stigmata of chronic liver disease
219 (CLD).

220

221 **Fig 4. Distribution of clinical examination findings among patients.**

222 CLD = chronic liver disease.

223 **Laboratory characteristics of patients**

224 Most of the participants had aspartate transferase (AST) and alanine transaminase
225 (ALT) levels within the normal range, 131(59.6%) and 195 (88.6%) respectively. One hundred
226 and eighty participants (81.8%) also had alkaline phosphatase (ALP) levels within the normal
227 range as shown in Table 2.

228

229 **Table 2. Liver function tests of study participants.**

Variables	Categories	Number (N =220)	Percentage (%)
AST (U/l)	Normal (0 – 31)	131	59.6
	Elevated (> 31)	89	40.4
ALT (U/l)	Low (< 13)	7	3.2
	Normal (13 – 69)	195	88.6
	Elevated (> 69)	18	8.2
ALP (U/l)	Low (<50)	15	6.8
	Normal (50 – 250)	180	81.8
	Elevated (> 250)	25	11.4
Direct bilirubin	Low (< 2)	28	12.7

230

($\mu\text{mol/l}$)	Normal (2 – 11)	163	74.5
	Elevated (> 11)	29	13.2
Albumin (g/dl)	Low (< 35)	33	15.0
	Normal (35 -52)	178	80.9
	Elevated (> 52)	9	4.1

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247 AST: Aspartate transferase, ALT: Alanine transaminase, ALP: Alkaline phosphatase

248

249

250

251 There was a small proportion of patients who had concomitant HIV and HCV infections,

252 2.7% and 1.4% respectively. Most of the patients (n = 85, 187%) had aspartate - platelet ratio

253 index (APRI) scores > 0.5. Also, 172 patients (78.2%) had HBV DNA levels \leq 2000 IU/ml

254 whereas 21.8% (n = 48) had levels > 2000 IU/ml. Only one patient (0.5%) had an HBV DNA

255 titer > 20,000 IU/ml (Table 3).

256

257 **Table 3. Other laboratory parameters of study participants.**

Clinical parameters	Variables	Number	Percentage (%)
HIV Status	Positive	6	2.7
	Negative	214	97.3
HCV Status	Positive	3	1.4
	Negative	217	98.6
APRI score	< 0.5	33	15
	0.5 – 2.0	186	84.5
	> 2.0	1	0.5
HBV DNA (IU/ml)	< 2000	172	78.2
	2000 – 20,000	47	21.3
	> 20,000	1	0.5

258 HIV: human immunodeficiency virus, HCV: hepatitis C virus, APRI: aspartate-platelet ratio
259 index, HBV: hepatitis B virus, DNA: deoxyribonucleic acid

260

261 The proportion of patients who tested positive for HBsAb and HBcAb were 6 (2.7%)
262 and 170 (77.3%) respectively. Also, 8 (3.6%) were seropositive for HBeAg whereas 177
263 (80.5%) showed seropositivity for HBeAb (Fig 5).

264

265 **Fig 5. HBV serological profile of patients.** HBsAb: hepatitis B surface antibody, HBeAg:
266 hepatitis B envelope antigen, hepatitis B envelope antibody, hepatitis B core antibody

267

268 **Treatment Eligibility**

269 In all, 14 participants (6.4%) were eligible for immediate initiation of antiviral therapy
 270 based on WHO guidelines [23]. This group comprised 8 (57.1%) males and 6 (42.9%) females
 271 (Table 4). All patients with e-antigen positive chronic hepatitis and/or APRI > 2 (HBV related
 272 cirrhosis or advanced fibrosis) required treatment as well as individuals with HCV/HIV
 273 coinfection and HCC. Among HBeAg-positive patients, treatment was required if ALT > 2x
 274 ULN or viral load $\geq 20,000$ IU/ml. For HBeAg-negative patients, indications for treatment were
 275 ALT $\geq 2x$ ULN or viral load ≥ 2000 IU/ml. None of the pregnant females in the study were
 276 found to be eligible for immediate commencement of antiviral therapy for HBV infection.
 277

278 **Table 4. Characteristics of patients who were eligible for antiviral therapy.**

Antiviral treatment eligibility	Number n/N	Percentage (%)
No antiviral treatment required	206/220	93.6
Treatment required:	14/220	6.4
Sex		
Male	8/14	57.1
Female	6/14	42.9
HBeAg status		
Positive	8/14	57.1
Negative	6/14	42.9
Serum ALT (U/l)		
$\leq 2x$ ULN	0/6	0
$> 2x$ ULN	6/6	100

Antiviral treatment eligibility	Number n/N	Percentage (%)
Pregnant women (n/N = 6/14)		
Requiring treatment or prophylaxis	0/6	0
Not requiring treatment or prophylaxis	6/6	100
Advanced liver disease		
APRI > 2	1/14	7.1
Cirrhosis on USG	0	0
HCC on USG	0	0
No cirrhosis or HCC	13	92.9
Co-infection status		
HIV-HBV co-infection	6/14	42.9
HCV-HBV co-infection	3/14	21.4

279 HBeAg: hepatitis B envelope antigen, ALT: Alanine transaminase, ULN: upper limit of normal
280 range, APRI: aspartate-platelet ratio index, USG: ultrasonography, HCC: hepatocellular
281 carcinoma, HIV: human immunodeficiency virus, HBV: hepatitis B virus, HCV: hepatitis C
282 virus.

283

284 Discussion

285 This study aimed to describe the clinical, immunological, and virological characteristics
286 of newly diagnosed HBV clients and assess their eligibility for antiviral treatment based on the
287 current WHO guidelines [23]. The median age of the participants in this study of 34 years is
288 comparable to the results of previous studies that were also focused on adult HBV patients \geq
289 18 years. In a meta-analysis of 30 peer reviewed publications with a population pool of over

290 100,000 Ghanaians, the authors reported the highest prevalence of HBV infection amongst
291 patients aged between 16 and 39 years [13]. In sub-Saharan Africa, HCC has been reported to
292 develop at a mean age of 33 years [24]. Individuals aged between 31 and 40 years have been
293 linked with a five-fold increase in the risk of HBV infection relative to other age groups
294 ($P=0.009$). The age range reported in this study represents both the reproductive and most
295 productive age groups in the Ghanaian society and may imply loss of productivity due to
296 absence from work for hospital visits and other economic activities among these patients.

297 There were 42 more females than males in our study population, representing 19.1% of
298 the total number of study participants. Two previous studies also reported a trend of higher
299 numbers of females compared to males in their studies involving patients with hepatitis B
300 infection [25, 26]. This study found a female to male ratio of 1.5:1 which can be partly
301 accounted for by the disparity in the general health seeking behavior among both sexes [27].
302 Women are more at risk of contracting STIs than men [28]. This translates into a higher
303 likelihood of disease transmission from men to women than vice versa [28]. Another study
304 confirmed the existence of gender disparity in the prevalence of infections caused by HBV
305 [29]. HBV infection is classified as a viral sexually transmitted disease together with other
306 infections such as HIV, HCV, HPV and HSV. Majority of the patients (65.0%) were sexually
307 active whereas the remainder were inactive. Sexual contact is key in the transmission HBV
308 infection among adults in areas with very high prevalence rates including Ghana. In Ghana,
309 mother-to-child transmission, unprotected intercourse, and transfusion of contaminated blood
310 are the three main ways that HBV is spread [30].

311 In our study, we found that 63.3% of the patients did not have any knowledge about the
312 status of their partners. This finding is not in keeping with the current WHO recommendation
313 of routine screening of partners of all patients diagnosed with HBV [31]. Infection of an
314 individual with HBV puts all close associates and immediate contacts such as spouses, sexual

315 partners, and household members at a high risk of getting infected. Disclosure of one's positive
316 HBsAg status to such exposed close contacts is vital in the prevention or alleviation of the risk
317 of transmission of HBV infection.

318 The disclosure of positive HBV status is very important for several reasons. First, it
319 provides an opportunity for the diagnosed individual to receive social support [32]. Close
320 contacts may be more likely to observe social protocols that will reduce their risk of being
321 infected (such as not sharing personal items like razor blades, nail cutters, tooth brushes or
322 anything that could have trace amounts of blood on them) and might be even more open to
323 HBV vaccination. Further studies are needed to explore the impact of HBV status disclosure
324 on the adoption of preventive measures and vaccination uptake among family members and
325 close associates of infected patients in the Ghanaian setting. Knowledge of the positive
326 diagnosis of a close contact is also an indication for HBsAg testing which will help in detecting
327 positive cases in family groups. Disclosure can also motivate other seropositive family
328 members to seek care thereby reducing their chance of developing cirrhosis and HCC.

329 In a study published in 2020 that investigated the disclosure of CHB status among HBV
330 infected patients in Ghana, it was reported that patients were more likely to disclose their status
331 under some conditions and for some reasons than others [33]. Reasons for disclosure included
332 the desire to have close contacts tested and vaccinated, willingness to confide in the target of
333 disclosure and the need for social and/or financial support. On the contrary, non-disclosures
334 were on account of phobia for stigmatization and past undesirable experiences associated with
335 disclosure.

336 Most of the participants were initially diagnosed via voluntary testing (62.7%) followed
337 by health worker recommendation (25.0%). Similar findings were reported in a previous study
338 that demonstrated that individuals with HBV infection were diagnosed because of self or
339 physician-initiated testing, testing during screening programs and ANC testing [26, 34]. The

340 findings of this study indicate that voluntary testing for HBsAg among the adult population is
341 very important in HBV infection case detection. Community based or opportunistic screening
342 undoubtedly remains an effective tool in picking up positive cases in the general population.

343 In our study, we found that majority of the patients (60.9%) were not aware of the HBsAg
344 status of their immediate family members. Out of those who knew the status of their family
345 members (n=85), majority (n=45, 52.9%) had family members who were known to be
346 seropositive for HBsAg. Therefore, the actual number of patients with a positive family history
347 for HBV infection is likely to be far greater. These findings suggest that intrafamilial spread of
348 HBV infection may be a potential mode of transmission in Ghana, and further studies are
349 needed to fully elucidate this theory.

350 The overall prevalence rate of HBsAg positivity was 20.5% among household members
351 of patients which is comparable to the rate of 23.3% reported in Iran [35]. A 2024 study in
352 Mwanza, Tanzania however reported a much lower HBV prevalence rate of 5.4% among
353 household contacts of index cases [36]. After testing positive for sexually transmitted diseases
354 like HIV and HBV, some individuals are more prone to concealing their diagnosis than seeking
355 medical attention due to stigmatization [37]. CHB infection is an incurable disease and hence,
356 some people may not want to be associated or tagged with this diagnosis. A qualitative study
357 on chronic hepatitis B stigma in Ghana found that people with hepatitis B experience societal
358 stigma underlined by the belief that HBV is a highly contagious and severe disease as well as
359 the notion that HBV infection arises due to curses [38]. The question of “the most probable
360 source of transmission” arises when individuals test positive for STIs. Some HBV positive
361 patients may not wish to disclose their status to their close contacts which will prompt them to
362 get tested. If this testing turns out positive, they would likely be viewed as the source of the
363 infection in the household simply because they were diagnosed first, though it could be the
364 other way around. Nondisclosure of HBsAg positive status to close contacts increases their risk

365 of contracting the disease. It also robs them of an indication for testing and treatment as well
366 as possibly HBV vaccination if eligible.

367 The median time interval between patient's initial diagnosis and presentation at the
368 specialist clinic was 8.5 months (IQR 3.0-22.5). Majority (61.8%) were seen < 1 year whereas
369 8.6% were seen > 5 years after initial diagnosis. The reasons for this delay in presentation at
370 the specialist clinic may be associated with both patient and primary care provider factors. In
371 several African countries including Ghana, many patients who test positive for HBsAg during
372 opportunistic screening are unable to afford the additional tests or the cost of therapy because
373 it must be paid for out-of-pocket [10, 13, 39]. As a result, a lot of patients who test positive for
374 HBV do not proceed immediately to seek medical care or do not complete the required initial
375 evaluation to determine what needs to be done for them. In Ghana, anecdotal evidence suggests
376 that some patients resort to traditional and/or herbal remedies for the initial management of
377 STIs such as HIV, HCV, and HBV as well as other health conditions including cancer, diabetes,
378 hypertensive heart disease and bronchial asthma[40-42]. As a result of this exploration and
379 experimentation with unorthodox medicine it is possible that some patients may present late to
380 the hospital after all other avenues have failed or when there is disease progression.

381 According to the WHO, as of 2019, 10.5% of all the people estimated to be HBsAg
382 positive already knew their positive status whereas only 22% of those diagnosed were receiving
383 medical care [4]. This points to the fact that a huge proportion of HBV infected patients do not
384 receive medical care after their diagnosis. Additionally, certain impediments to HBV treatment
385 and care have been reported including barriers relating to sociocultural beliefs and health
386 systems. These sociocultural beliefs include the perception that HBV is a spiritual disease and
387 a form of punishment from God. On the individual level, some patients take HBV infection for
388 granted owing to the absence of specific symptoms of CHB [33]. Furthermore, the financial
389 burden of hospital-centered treatment for HBV infection is considerably high and even

390 prohibitive for some patients [43] . In Ghana, unlike patients with HIV or HBV/HIV
391 coinfection, HBV mono-infected patients must pay for their medications out of pocket in
392 addition to the cost of their routine investigations such as LFT, HBV immunological profile
393 and hepatitis B viral load. The inclusion of medications, laboratory analysis and other
394 investigations under the National Health Insurance Scheme (NHIS) could potentially remove
395 this barrier at least partially if not completely. Similar to findings in other countries such as
396 Burkina Faso and Australia, the delay in seeking care for HBV infection could also be because
397 of stigmatization (or fear of it thereof), lack of knowledge and misconceptions about HBV
398 treatment as well as long queues and waiting times at treatment facilities [44, 45].

399 Hepatitis B infection is known to be self-limiting in 95% of adult cases and 5-15% of
400 cases among children under five years. According to WHO, 6.6 million (22%) of the people
401 diagnosed with HBV were on treatment as of 2019. The percentage of patients diagnosed with
402 HBV in Ghana who require treatment as well as the proportion of these treatment eligible
403 patients who receive the required treatment is unknown. In 2021 the proportion of CHB patients
404 worldwide who required treatment was about 12 - 25% (WHO 2021). There is no specific
405 treatment for acute hepatitis B unless the patient has acute hepatic failure, but for most patients,
406 antiviral treatment for CHB is lifelong. This has direct cost implications and potential financial
407 toxicity.

408 Treatment for viral hepatitis in Ghana is based on the National Guidelines for
409 Prevention, Care and Treatment of viral hepatitis which is in line with the treatment
410 recommendations of the World Health Organization. Approved antiviral agents for treatment
411 of HBV infection in Ghana include Tenofovir disoproxil fumarate, Entecavir, pegylated
412 interferon and Emtricitabine among several others. The treatment eligibility rate of 6.4%
413 reported in this study is much lower than the reported rate of 46.8% in the United States [46].
414 This low rate implies that a significant proportion of the patients were diagnosed at a stage of

415 the disease that required close monitoring but did not warrant the immediate initiation of
416 expensive antiviral therapy which is not affordable for many patients.

417 Early and appropriate initiation of therapy for HBV infection is important in the
418 reduction of the risk of transmission and development of fatal long-term complications. To be
419 able to accomplish the WHO goal of eliminating viral hepatitis by the year 2030, it is important
420 to not only precisely estimate treatment eligibility rates but also to ensure high treatment rates.
421 To the best of our knowledge based on currently available literature this is the first study that
422 evaluates treatment eligibility (rate) among HBV infected patients seeking medical care in the
423 Central Region of Ghana. Evaluation of treatment rate i.e., proportion of patients eligible for
424 treatment who receive antiviral treatment was beyond the scope of this study and remains an
425 outstanding question for future studies.

426

427 **Limitations**

428 This study was conducted among patients who had voluntarily reported at the HBV/other
429 STIs clinic to seek medical care for HBV infection and thus did not include in-patients admitted
430 at the medical emergency unit or on the medical wards for complications of hepatitis B
431 infection. Neither did the study capture HBV patients who were not seeking hospital-based
432 care at all. Thus, the results of this study may potentially underestimate the prevalence of
433 advanced disease among HBsAg seropositive patients.

434 **Conclusions**

435 This study reports a high level of HBsAg positivity rate among close family members of
436 HBV positive persons. Nonetheless, there is very low adherence to the requirement of
437 screening of close family members of index cases. There is a very low treatment eligibility rate
438 among patients seeking medical care for HBV infection. There was low prevalence of both
439 HIV and HCV coinfections without any recorded cases of triple infections.

440 References

- 441 1. Razavi-Shearer, D., et al., *Global prevalence, cascade of care, and prophylaxis coverage*
442 *of hepatitis B in 2022: a modelling study*. The Lancet Gastroenterology & Hepatology,
443 2023. **8**(10): p. 879-907.
- 444 2. Schweitzer, A., et al., *Estimations of worldwide prevalence of chronic hepatitis B virus*
445 *infection: a systematic review of data published between 1965 and 2013*. The Lancet,
446 2015: p. 386(10003):1546-55.
- 447 3. Ott, J.J., et al., *Global epidemiology of hepatitis B virus infection: new estimates of age-*
448 *specific HBsAg seroprevalence and endemicity*. Vaccine, 2012. **30**(12): p. 2212-9.
- 449 4. WHO. *Hepatitis B, Key facts*. WHO 2019 July 18; Available from:
450 <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>.
- 451 5. Venook, A.P., et al., *The incidence and epidemiology of hepatocellular carcinoma: a*
452 *global and regional perspective*. Oncologist, 2010. **15 Suppl 4**(S4): p. 5-13.
- 453 6. Lavanchy, D., *Hepatitis B virus epidemiology, disease burden, treatment, and current and*
454 *emerging prevention and control measures*. J Viral Hepat, 2004. **11**(2): p. 97-107.
- 455 7. Sonderup, M.W. and C.W. Spearman, *Global Disparities in Hepatitis B Elimination-A*
456 *Focus on Africa*. Viruses, 2022. **14**(1).
- 457 8. Yang, W.T., et al., *Hepatitis B Surface Antigen Loss and Hepatocellular Carcinoma*
458 *Development in Patients With Dual Hepatitis B and C Infection*. Medicine (Baltimore),
459 2016. **95**(10): p. e2995.
- 460 9. Blankson, A., et al., *Sero-prevalence of Hepatitis B and C viruses in cirrhosis of the liver*
461 *in Accra, Ghana*. Ghana medical journal., 2005: p. 39(4):132.
- 462 10. Nartey, Y.A., et al., *A nationwide cross-sectional review of in-hospital hepatitis B virus*
463 *testing and disease burden estimation in Ghana, 2016-2021*. BMC Public Health, 2022.
464 **22**(1): p. 1-15.

- 465 11. Teye, J., *Ghana risks losing productive youth to Hepatitis*, in *Myjoyonline.com*. 2015.
- 466 12. Abesig, J., et al., *Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A*
467 *systematic review and meta-analysis*. *PloS one*, 2020. **15**(6): p. e0234348.
- 468 13. Ofori-Asenso, R. and A.A. Agyeman, *Hepatitis B in Ghana: a systematic review & meta-*
469 *analysis of prevalence studies (1995-2015)*. *BMC Infect Dis*, 2016. **16**: p. 130.
- 470 14. Organization, W.H. and *Global hepatitis report 2017*. 2017.
- 471 15. EASL, *Clinical Practice Guidelines on the management of hepatitis B virus infection*.
472 *Journal of hepatology*, 2017: p. 67(2):370-98.
- 473 16. Terrault, N.A., et al., *AASLD guidelines for treatment of chronic hepatitis B*. *Hepatology*,
474 2016. **63**(1): p. 261-83.
- 475 17. Blumberg, B.S., *The discovery of Australia antigen and its relation to viral hepatitis*. 1971.
- 476 18. Saldanha, J., et al., *An international collaborative study to establish a World Health*
477 *Organization international standard for hepatitis B virus DNA nucleic acid amplification*
478 *techniques*. *Vox Sang*, 2001. **80**(1): p. 63-71.
- 479 19. Wang, J., et al., *Analytical comparison between two hematological analyzer systems:*
480 *Mindray BC-5180 vs Sysmex XN-1000*. *J Clin Lab Anal*, 2019. **33**(8): p. e22955.
- 481 20. Branson, B.M., et al., *Revised recommendations for HIV testing of adults, adolescents,*
482 *and pregnant women in health-care settings*. *MMWR Recomm Rep*, 2006. **55**(RR-14): p.
483 1-17; quiz CE1-4.
- 484 21. Smith, B.D., et al., *Rapid diagnostic HCV antibody assays*. *Antivir Ther*, 2012. **17**(7 Pt
485 B): p. 1409-13.
- 486 22. Wai, C.T., et al., *A simple noninvasive index can predict both significant fibrosis and*
487 *cirrhosis in patients with chronic hepatitis C*. *Hepatology*, 2003. **38**(2): p. 518-26.
- 488 23. Organization, W.H., *Guidelines for the prevention care and treatment of persons with*
489 *chronic hepatitis B infection: Mar-15*. 2015: World Health Organization.

- 490 24. Howell, J., M. Lemoine, and M. Thursz, *Prevention of materno-foetal transmission of*
491 *hepatitis B in sub-Saharan Africa: the evidence, current practice and future challenges.* J
492 Viral Hepat, 2014. **21**(6): p. 381-96.
- 493 25. Antwi-Baffour, S.S., et al., *Incidence of hepatitis B surface antigen among sickle cell*
494 *disease patients receiving transfusion therapy.* Int J Biomed Sci Engineering, 2014. **2**(1):
495 p. 7-10.
- 496 26. Adjei, A.A., et al., *Correlates of HIV, HBV, HCV and syphilis infections among prison*
497 *inmates and officers in Ghana: A national multicenter study.* BMC infectious diseases,
498 2008. **8**(1): p. 1-12.
- 499 27. Fenny, A.P., et al., *Who uses outpatient healthcare services under Ghana's health*
500 *protection scheme and why?* BMC Health Serv Res, 2016. **16**(1): p. 174.
- 501 28. Coombs, R.W., P.S. Reichelderfer, and A.L. Landay, *Recent observations on HIV type-1*
502 *infection in the genital tract of men and women.* AIDS, 2003. **17**(4): p. 455-80.
- 503 29. Baig, S., *Gender disparity in infections of Hepatitis B virus.* J Coll Physicians Surg Pak,
504 2009. **19**(9): p. 598-600.
- 505 30. Candotti, D. and J.P. Allain, *Transfusion-transmitted hepatitis B virus infection.* J Hepatol,
506 2009. **51**(4): p. 798-809.
- 507 31. Vittal, A. and M.G. Ghany, *WHO Guidelines for Prevention, Care and Treatment of*
508 *Individuals Infected with HBV: A US Perspective.* Clin Liver Dis, 2019. **23**(3): p. 417-432.
- 509 32. Kittner, J.M., et al., *Disclosure behaviour and experienced reactions in patients with HIV*
510 *versus chronic viral hepatitis or diabetes mellitus in Germany.* AIDS Care, 2013. **25**(10):
511 p. 1259-70.
- 512 33. Adjei, C.A., et al., *"To die is better than to tell": reasons for and against disclosure of*
513 *chronic hepatitis B status in Ghana.* BMC public health, 2020. **20**(1): p. 1-9.

- 514 34. Kafeero, H.M., et al., *Sero-prevalence of human immunodeficiency virus-hepatitis B virus*
515 *(HIV-HBV) co-infection among pregnant women attending antenatal care (ANC) in sub-*
516 *Saharan Africa (SSA) and the associated risk factors: a systematic review and meta-*
517 *analysis*. *Virologia*, 2020. **17**(1): p. 170.
- 518 35. Sofian, M., et al., *Intra-familial Transmission of Hepatitis B Virus Infection in Arak,*
519 *Central Iran*. *Iran J Pathol*, 2016. **11**(4): p. 328-333.
- 520 36. Mangowi, I., et al., *Hepatitis B virus infection, associated factors, knowledge and*
521 *vaccination status among household contacts of hepatitis B index cases in Mwanza,*
522 *Tanzania*. *IJID Reg*, 2024. **10**: p. 168-173.
- 523 37. Mahajan, A.P., et al., *Stigma in the HIV/AIDS epidemic: a review of the literature and*
524 *recommendations for the way forward*. *AIDS*, 2008. **22 Suppl 2**(Suppl 2): p. S67-79.
- 525 38. Adjei, C.A., et al., *Chronic Hepatitis B stigma in Ghana: a qualitative study with patients*
526 *and providers*. *BMJ Open*, 2019. **9**(6): p. e025503.
- 527 39. Lemoine, M., S. Eholie, and K. Lacombe, *Reducing the neglected burden of viral hepatitis*
528 *in Africa: strategies for a global approach*. *J Hepatol*, 2015. **62**(2): p. 469-76.
- 529 40. Kwasi Kumah, F., et al., *Assessment of public opinion on the use of herbal medicine for the*
530 *treatment of sexually transmitted infections (STI) in accra*. *Traditional Medicine and*
531 *Modern Medicine*, 2024. **7**: p. 1-12.
- 532 41. Aziato, L. and H.O. Antwi, *Facilitators and barriers of herbal medicine use in Accra,*
533 *Ghana: an inductive exploratory study*. *BMC Complement Altern Med*, 2016. **16**: p. 142.
- 534 42. Amegbor, P.M., *Understanding usage and preference for health care therapies in a*
535 *Ghanaian context: A pluralistic perspective*. *Norsk Geografisk Tidsskrift-Norwegian*
536 *Journal of Geography*, 2017. **71**(5): p. 288-300.

- 537 43. Nartey, Y.A., et al., *A nationwide cross-sectional review of in-hospital hepatitis B virus*
538 *testing and disease burden estimation in Ghana, 2016 - 2021*. BMC Public Health, 2022.
539 **22**(1): p. 2149.
- 540 44. Guirgis, M., et al., *Barriers faced by migrants in accessing healthcare for viral hepatitis*
541 *infection*. Intern Med J, 2012. **42**(5): p. 491-6.
- 542 45. Giles-Vernick, T., et al., *Barriers to Linkage to Care for Hepatitis B Virus Infection: A*
543 *Qualitative Analysis in Burkina Faso, West Africa*. Am J Trop Med Hyg, 2016. **95**(6): p.
544 1368-1375.
- 545 46. Wong, R.J., et al., *Low rates of hepatitis B virus treatment among treatment-eligible*
546 *patients in safety-net health systems*. Journal of Clinical Gastroenterology, 2022. **56**(4): p.
547 360-368.
- 548




Figure 1




Figure 2





Figure 3



■ Abdominal distension
 ■ Cachexia
 ■ Hepatomegaly
 ■ Jaundice
 ■ Other CLD stigmata

Figure 4




Figure 5